Title: Up-regulated expression of type II very low density lipoprotein receptor correlates with cancer metastasis and has a potential link to beta-catenin in different cancers Thank you very much for your comments and suggestions. We have revised the manuscript, and responded point by point to the comments as listed below according to the comments and suggestions of reviewers and editors. I would like to re-submit this revised manuscript to BMC Cancer, and hope it is acceptable for publication on the journal. First of all, we thank both editors and reviewers for their positive and constructive comments and suggestions. Our responses to the editor's and reviewer's concerns are listed below. In this study, all patients who had undergone surgical resection gave informed consent to use excess pathological specimens for research purposes. Research was aslo carried out in compliance with Helsinki Declaration with the approval of the Ethics Committee of tongji medical college (Email: tongjilunli@163.com). According to your advices, the statement to this effect have been added into the part of methods of the revised manucript (Page 6, line 21), which have been underlined in red color. (1) Is there any relationship between VLDLRⅡ expression and other clinical features including body weight and plasma lipid profiles (such as triglycerides and so on). Answer: We really neglected the relationship between VLDLRⅡ expression and some clinical features including body weight and plasma lipid profiles. We understand Dr. Yamada' point, and accept the suggestion. Thus, we consulted the medical records of cancer patients again, and analysed the relationship between VLDLRⅡ expression and additional clinical features (such as body weight, triglycerides, and total cholesterol). Please refer to Table 2, Table 3 and Table 5 in the revised manuscript. The results showed that VLDLRⅡ expression in cancer tissues was not significantly associated with body weight, total cholesterol and triglycerides. Maybe the lipid content are impacted by comprehensive factor.
[1]
Zhiguo Liu,et al.
Enhanced activity of very low density lipoprotein receptor II promotes SGC7901 cell proliferation and migration.
,
2009,
Life sciences.
[2]
Peter Carmeliet,et al.
VEGF as a Key Mediator of Angiogenesis in Cancer
,
2005,
Oncology.
[3]
B. Angelin,et al.
Dexamethasone stimulates very low density lipoprotein (VLDL) receptor gene expression in differentiating 3T3-L1 cells.
,
2002,
Biochimica et biophysica acta.
[4]
J. Jośko,et al.
Vascular endothelial growth factor (VEGF) and its effect on angiogenesis.
,
2000,
Medical science monitor : international medical journal of experimental and clinical research.
[5]
Y. Kawarabayasi,et al.
Rabbit very low density lipoprotein receptor: a low density lipoprotein receptor-like protein with distinct ligand specificity.
,
1992,
Proceedings of the National Academy of Sciences of the United States of America.